Medinice
Medinice is a medical technology company developing minimally invasive cardiac devices for cardiology and cardiac surgery.
- Public company
- Warsaw, PLPoland
Medinice is a medical technology company developing minimally invasive cardiac devices for cardiology and cardiac surgery.
medinice.plCrawled Nov 11, 2026
AtriClamp closes the left atrial appendage to reduce stroke risk in atrial fibrillation patients by preventing thrombus formation.
CoolCryo uses liquid nitrogen for cardiac cryoablation, offering cost-effective cooling, a heated tip for fast ablation, and shorter procedure times.
Medinice outlines its development timeline for technologies advancing cardiology and cardiac surgery.
MiniMax is an ablation-mapping catheter used for detecting intracardiac electrophysiological signals, creating a 3D map of the heart, and performing intracardiac irrigated RF ablation to treat arrhythmias caused by abnormalities in the heart’s conduction system.
Medinice S.A. completed clinical investigations for CoolCryo, with all participants finishing follow-up and enabling next-stage regulatory and commercialization steps.
Medinice S.A. is in the final stage of discussions and negotiations with an entity from the DACH region regarding a potential transaction and further cooperation in the field of Pulsed Field Ablation (PFA) technology.
Medinice S.A. received FDA clearance for its CoolCryo device under the 510(k) procedure, allowing market entry in the United States.
Medinice’s leadership team combines industry expertise, a focus on medical innovation, and a commitment to improving patient outcomes in cardiac medicine.
Medinice S.A., founded in 2012, develops medical devices to address unmet needs in cardiology and cardiac surgery, focusing on minimally invasive solutions.
Medinice S.A. implements projects funded by European programs, detailing goals, effects, budgets, and funding amounts for each initiative.
Medinice S.A. creates and commercializes minimally invasive cardiology and cardiac surgery solutions to improve patient quality of life, with projects at various development stages.
Medinice is finalizing talks with a DACH region partner. Instead of an equity acquisition, the company is negotiating the takeover of selected advanced PFA projects, requiring less capital and providing greater financial flexibility.